AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination
HUTCHMED said AstraZeneca applied to the FDA for approval of the ORPATHYS-TAGRISSO combination for advanced lung cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results.
AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination
HUTCHMED (China) HKEX:13 said on Tuesday that Anglo-Swedish drugmaker AstraZeneca LSE:AZN had applied to the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination to treat patients with advanced lung cancer.ORPATHYS is being jointly developed by AstraZeneca and HUTCHMED…
AstraZeneca files US FDA application for ORPATHYS-TAGRISSO lung cancer combination
HUTCHMED said AstraZeneca filed the application for approval in advanced lung cancer patients.
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination
HUTCHMED (China) HKEX:13 said on Tuesday Anglo-Swedish drugmaker AstraZeneca LSE:AZN had filed an application with the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination in patients with advanced lung cancer.ORPATHYS is being jointly developed by AstraZeneca and HUTCH…